Management of Portal vein Thrombosis in Cirrhosis

Area of Science:

• Hepatology
• Gastroenterology
• Vascular Medicine

Background:

• Portal vein thrombosis (PVT) is a frequent complication of cirrhosis, with incidence correlating to liver disease severity.
• PVT can exacerbate ascites, increase risks of variceal bleeding, and negatively impact liver transplant outcomes.
• Certain medications like statins may prevent PVT, while beta-blockers might increase its occurrence.

Purpose of the Study:

• To review current knowledge on the diagnosis and management of PVT in patients with cirrhosis.
• To highlight the role of anticoagulation and other treatment modalities for PVT in this population.
• To discuss the implications of PVT on liver disease progression and transplantation.

Main Methods:

• Review of current literature on PVT in cirrhosis.
• Analysis of diagnostic imaging techniques for PVT classification.
• Evaluation of therapeutic strategies including anticoagulation and transjugular intrahepatic portosystemic shunt (TIPS).

Main Results:

• PVT incidence is higher in advanced cirrhosis (Child-Turcotte-Pugh C), with large shunts, hepatofugal flow, and hepatocellular carcinoma.
• Anticoagulation is indicated for symptomatic, occlusive PVT and transplant candidates, with Vitamin K antagonists, LMWH, and newer agents demonstrating safety and efficacy.
• Direct-acting oral anticoagulants are preferred in early cirrhosis (CTP A, B).

Conclusions:

• Effective management of PVT in cirrhosis necessitates individualized treatment plans, considering disease severity and patient-specific factors.
• Anticoagulant therapy duration, response prediction, and complication management require specialized knowledge.
• TIPS serves as an alternative for non-responsive cases or when anticoagulation is contraindicated.